Vistagen Therapeutics Net Tangible Assets

As of the most recent data (March 2026), VTGN shows a net tangible assets of $36M. That compares with $70M in the prior-year period — down 49.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, VTGN's net tangible assets is now $36M (was $70M) — a 49.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Vistagen Therapeutics is outperforming or lagging.

Tracking VTGN's net tangible assets over time shows whether Vistagen Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $36M That compares with $70M in the prior-year period — down 49.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Vistagen Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $36M) with ownership activity and broader fundamentals.

Vistagen Therapeutics's net tangible assets is $36M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.